Competitive LRRK2 kinase inhibitor without affecting the GTPase activity

Precursor of 6-[18F]Fluoro-L-DOPA used for positron emission tomography (PET) scans. References: http://www.hindawi.com/journals/bmri/2014/674063/

Nucleic acid binding fluorescent dye

Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors

Novel partial agonist of PPARα and PPARγ, providing distinct and favorable gene activation profiles for the treatment of diabetes and obesity

Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors

Highly potent multi-target antagonists of alpha1A- and alpha1D-adrenoceptors, and 5-HT1A receptors

Novel inhibitor of the LEDGF/p75-IN interaction, potently inhibiting both the early and late stages of HIV-1 replication

Cyclooxygenase-2 (COX-2) inhibitor

Novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist

Novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5

Novel inhibitor of nuclear receptor binding SET domain 2 (NSD2), against H3K36 methylation

Novel inhibitor of T-cell expansion and autoimmune encephalomyelitis

Novel Electrophilic PROTAC that degrades nuclear proteins by engaging DCAF16

Phosphodiesterase inhibitor, acting as a vasodilator and showing antihypertensive effects

Novel non-steroidal glucocorticoid receptor agonist

Novel Soft-Drug Inhibitor of Phosphodiesterase 4 (PDE4) for Topical Treatment of Atopic Dermatitis

Orally bioavailable Smoothened (Smo) antagonist

Leukotriene B4 receptor antagonist

Inhibitor of ERAAP function

Partial agonist (antagonist) at mu and delta opioid receptors.

Watersoluble prodrug of Levcromakalim, being more chemically robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model.